-- Seikagaku (TYO:4548) said it received marketing approval in Japan for its adhesion barrier SI-449 and selected Covidien Japan as its sales partner, according to a Wednesday filing on the Tokyo Stock Exchange.
The product, to be marketed as cs barrier, is used to prevent postoperative adhesions. Launch timing will be decided after insurance reimbursement pricing is set.